Tysabri and PML: Who May Be at Risk Based on Published Reports

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance research have established that certain patient factors, such as JC virus antibody status and duration of therapy, are linked to higher PML risk. This page reviews published reports and FDA labeling to clarify who may be at risk and what monitoring is recommended.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning underscores the gravity of the adverse event and the need for careful patient selection and monitoring. PML is a demyelinating disease that occurs almost exclusively in immunocompromised individuals. The JC virus, which is typically latent in healthy people, reactivates under conditions of immune suppression and infects oligodendrocytes in the brain, leading to progressive neurological damage. A retrospective national cohort study of 456 Italian PML patients observed between 1987 and 2024 described the condition as a "severe demyelinating disease caused by JC polyomavirus (JCV), affecting immunocompromised individuals" (https://pubmed.ncbi.nlm.nih.gov/40922664/). Clinical presentation of PML can include progressive weakness, visual disturbances, cognitive decline, and coordination problems, often leading to severe disability or death.

Mechanistic Pathway and Risk Factors for PML

The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration from the bloodstream into the central nervous system. While this reduces inflammatory activity in conditions like multiple sclerosis, it also impairs immune surveillance in the brain. This creates an environment where the JC virus can replicate unchecked, leading to PML. The FDA label notes that PML "has occurred in patients who have received TYSABRI" and identifies three key risk factors: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who test positive for anti-JCV antibodies have a higher risk, and the risk increases with longer treatment duration, especially beyond two years. Prior use of immunosuppressive medications further elevates this risk.

Clinical Trial Evidence and Warning Adequacy

Clinical trial data provide evidence of the association between Tysabri and PML. According to the FDA label, "PML occurred in three patients who received TYSABRI in clinical trials" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Specifically, two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks, and both had received Tysabri in addition to interferon beta-1a. A third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML. These cases highlight the real-world risk and the need for vigilance. The adequacy of warnings regarding Tysabri and PML is a critical consideration for affected patients. The FDA boxed warning explicitly states that "TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML)" and advises that "these factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also mandates that "healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients and their families may argue that the risks were not adequately communicated or that the monitoring protocols were insufficient to prevent harm.

Settlement Considerations for Tysabri-Related PML

For patients who develop PML after Tysabri treatment, settlement-related considerations may arise. The timeline between exposure and documented harm is variable. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, post-marketing cases have been reported at various intervals, and the risk appears to increase with cumulative exposure. Patients who suffer from PML may face substantial medical costs, loss of income, and diminished quality of life. Legal claims often focus on whether the manufacturer provided adequate warnings and whether the benefits of Tysabri were properly weighed against the known risks. Settlement amounts can vary based on the severity of the injury, the degree of disability, and the strength of the evidence regarding warning deficiencies. In summary, Tysabri is associated with a significant risk of PML, a devastating brain infection that can lead to death or severe disability. The FDA has issued a boxed warning highlighting this risk and identifying key factors such as anti-JCV antibody status, treatment duration, and prior immunosuppressant use. Clinical trial data confirm the occurrence of PML in Tysabri-treated patients. For those affected, the adequacy of warnings and the timeline of harm are central to settlement considerations. Patients and their families should seek legal counsel to evaluate their options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Tysabri and Progressive Multifocal Leukoencephalopathy (PML)?

Tysabri (natalizumab) increases the risk of PML, a severe brain infection caused by the JC virus. The FDA has issued a boxed warning stating that Tysabri "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk is higher in patients with anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use.

What are the symptoms of PML in Tysabri patients?

Symptoms of PML include progressive weakness, visual disturbances, cognitive decline, and coordination problems. These symptoms can lead to severe disability or death. The FDA label advises healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately if such symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can I file a lawsuit or seek a settlement if I developed PML from Tysabri?

Yes, patients who developed PML after Tysabri treatment may have legal options. Claims often focus on whether the manufacturer provided adequate warnings about the risk of PML. Settlement amounts depend on the severity of injury, disability, and evidence of warning deficiencies. It is advisable to consult with an experienced attorney to evaluate your case.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.